Guilford Files Shelf Registration Statement
May 20 2004 - 4:48PM
PR Newswire (US)
Guilford Files Shelf Registration Statement BALTIMORE, May 20
/PRNewswire-FirstCall/ -- Guilford Pharmaceuticals Inc. announced
today that it has filed a universal shelf registration statement
with the Securities and Exchange Commission. When the registration
statement becomes effective, it will permit Guilford, from time to
time, to offer and sell common stock, debt securities, warrants,
and preferred stock, in any combination, up to a total value of
$100 million. A registration statement relating to these securities
has been filed with the Securities and Exchange Commission but has
not yet become effective. These securities may not be sold, nor may
offers to buy be accepted, prior to the time the registration
statement becomes effective. This press release shall not
constitute an offer to sell or the solicitation of an offer to buy
nor shall there be any sale of these securities in any state in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state. About Guilford Guilford Pharmaceuticals Inc. is a fully
integrated pharmaceutical company engaged in the research,
development and commercialization of products that target the
hospital market. Presently, Guilford markets two commercial
products, GLIADEL(R) Wafer (polifeprosan 20 with carmustine
implant) and AGGRASTAT(R) Injection (tirofiban hydrochloride).
Additional information about GLIADEL and AGGRASTAT, including
safety information, may be found at http://www.guilfordpharm.com/ /
Products / Marketed Products / GLIADEL, or at
http://www.aggrastat.com/. Guilford's product pipeline includes a
novel anesthetic, AQUAVAN(R) Injection, and drugs for treating
Parkinson's disease and post- prostatectomy erectile dysfunction.
CONTACT: Stacey Jurchison, Director, Corporate Communications,
Guilford Pharmaceuticals, (410) 631-5022; .
http://www.guilfordpharm.com/. DATASOURCE: Guilford Pharmaceuticals
Inc. CONTACT: Stacey Jurchison, Director, Corporate Communications,
Guilford Pharmaceuticals, +1-410-631-5022, Web site:
http://www.aggrastat.com/ Web site: http://www.guilfordpharm.com/
Company News On-Call: http://www.prnewswire.com/comp/112882.html
Copyright
Guilford (NASDAQ:GLFD)
Historical Stock Chart
From Nov 2024 to Dec 2024
Guilford (NASDAQ:GLFD)
Historical Stock Chart
From Dec 2023 to Dec 2024
Real-Time news about Guilford Pharmaceuticals (MM) (NASDAQ): 0 recent articles
More Guilford Pharmaceuticals (MM) News Articles